Skip to main content
    S

    Sagimet Biosciences Inc. Series A Common Stock (SGMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.13
    -0.09 (-0.88%)

    Market Cap: $735.18M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sagimet Biosciences Inc. Series A Common Stock (SGMT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Sagimet Biosciences Inc. Series A Common Stock (SGMT) to earn -$1.25 per share in the fiscal year ending Dec 31, 2026. Of 12 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.

    RatingAnalystsShare
    Strong Buy216.7%
    Buy975.0%
    Hold00.0%
    Sell18.3%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    12

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Dec 31, 2026
    -$1.25
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$1.35
    EPS consensus, revenue $13.18M

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.25-$1.52 to -$1.157N/AN/A10
    Dec 31, 2027-$1.35-$2.43 to -$0.3910$13.18MN/A7

    Quarterly Estimates

    The EPS consensus rises from -$0.29 for the quarter ending Dec 31, 2026 to -$0.27 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.29-$0.35 to -$0.2214N/AN/A13
    Mar 31, 2027-$0.27-$0.30 to -$0.224$2.96M$930000 to $5.00M2

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 9 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202640
    Fiscal year ending Dec 31, 202750

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.20.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.25-$1.12-$1.12-$1.16-$1.20N/A
    Fiscal year ending Dec 31, 2027-$1.35-$1.30-$1.30-$1.37-$1.34N/A
    Quarter ending Mar 31, 2027-$0.27-$0.29-$0.29-$0.34-$0.33N/A

    Frequently Asked Questions About SGMT

    What is the SGMT stock forecast?

    Consensus analyst estimates put Sagimet Biosciences Inc. Series A Common Stock's EPS at -$1.25 for the fiscal year ending Dec 31, 2026. The consensus rating from 12 analysts is Buy.

    How do analysts rate SGMT stock?

    Of 12 analysts covering Sagimet Biosciences Inc. Series A Common Stock, 2 rate it Strong Buy, 9 Buy, 0 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from SGMT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.25, with estimates from -$1.52 to -$1.15 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.35, with estimates from -$2.43 to -$0.39 from 10 analysts.

    What revenue do analysts expect from Sagimet Biosciences Inc. Series A Common Stock next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $13.18M.

    How many analysts cover SGMT?

    12 analysts rate Sagimet Biosciences Inc. Series A Common Stock stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.